Production (Stage)
NurExone Biologic Inc.
NRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.68M | -1.55M | -1.25M | -1.33M | -922.00K |
| Total Depreciation and Amortization | 43.00K | 39.00K | 18.00K | 13.00K | 15.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 313.00K | 333.00K | 316.00K | 320.00K | 24.00K |
| Change in Net Operating Assets | 336.00K | -561.00K | 98.00K | 122.00K | -582.00K |
| Cash from Operations | -986.00K | -1.74M | -818.00K | -870.00K | -1.47M |
| Capital Expenditure | -32.00K | -46.00K | -301.00K | -61.00K | -241.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 1.00K | 0.00 | -10.00K | -- |
| Cash from Investing | -32.00K | -45.00K | -301.00K | -71.00K | -241.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.00K | -7.00K | -8.00K | -7.00K | -8.00K |
| Issuance of Common Stock | 913.00K | 1.46M | 877.00K | 15.00K | 4.41M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -1.28M | 390.00K | 36.00K | -- |
| Cash from Financing | 910.00K | 177.00K | 1.26M | 44.00K | 4.40M |
| Foreign Exchange rate Adjustments | -4.00K | -220.00K | -2.00K | 27.00K | 22.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.00K | -1.82M | 138.00K | -870.00K | 2.71M |